Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bernstein Downgrades Lam Research to Market Perform

Bernstein analyst Stacy Rasgon downgrades Lam Research (NASDAQ:LRCX) from Outperform to Market Perform.
byBenzinga Newsdesk
March 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Bernstein analyst Stacy Rasgon downgrades Lam Research (NASDAQ:LRCX) from Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Disc Medicine Announces Planned Departure Of Chief Financial Officer Joanne Bryce; Co Initiated A Search To Fill The Position. Ms. Bryce Plans To Remain With The Co And Oversee Her Current Responsibilities Until A Successor Has Been Identified

By Happy Mohamed
October 23, 9:17 AM
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,

IRON